Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
IBIO Stock Summary
Top 10 Correlated ETFs
IBIO
In the News
iBio stock nearly tripled on Wednesday: here's why
Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.
iBio partners with AstralBio to develop obesity treatments using AI-driven platform
iBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. The company said the collaboration brings together its ability to create antibodies against hard-to-drug targets using its patented Generative AI and machine learning platform with AstralBio's experience in biologics and drug development.
Why Is iBio (IBIO) Stock Up 125% Today?
iBio‘s (NYSEMKT: IBIO ) shares are trending, and IBIO stock is up 125% today after the firm used two of the market's favorite buzzwords — artificial intelligence (AI) and obesity drugs — in a press release that unveiled a new initiative. Specifically, the firm announced that its AI drug discovery platform would be used to develop obesity treatments.
Why Is iBio (IBIO) Stock Down 41% Today?
Ibio (NYSEMKT: IBIO ) stock is falling hard on Tuesday after the biotechnology company announced the pricing of a public share offering. That offering has the company selling 2.25 million shares of IBIO stock for $2 each.
Ticking Time Bombs: 3 Healthcare Stocks to Dump Before the Damage Is Done
The healthcare industry has historically provided significant returns to investors. And, it is currently boasting a compounding annual growth rate prediction of 10.4% until 2027.
Why Is iBio (IBIO) Stock Up 16% Today?
Ibio (NYSEMKT: IBIO ) stock is rising higher on Tuesday as investors react to the company reaching a research collaboration agreement with the NIH. This will see the company teaming up with the NIH's National Institute of Allergy and Infectious Diseases (NIAID).
Penny Stocks To Buy Now? 3 Short Squeeze Stock To Watch
Short squeeze penny stocks for your watch list. The post Penny Stocks To Buy Now?
7 Stocks to Sell as Banks Melt Down
Peruse the Internet for investment guidance and you're likely to hear the adage that you shouldn't consider stocks to sell when faced with volatility. Rather, you should buy up assets and securities when there's blood on the streets.
4 Top Penny Stocks To Watch With Big Biotech News This Quarter
4 biotech penny stocks to watch right now. The post 4 Top Penny Stocks To Watch With Big Biotech News This Quarter appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Buy: 5 To Watch Before Next Week
Penny stocks to watch this week. The post Penny Stocks To Buy: 5 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
IBIO Financial details
IBIO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.67 | 0.65 | 0.3 | 0.27 | 0 | |
Net income per share | -23.24 | -7.53 | -2.97 | -5.85 | -2.39 | |
Operating cash flow per share | -18.46 | -5.31 | -3.84 | -4.3 | -2.49 | |
Free cash flow per share | -19.77 | -5.77 | -4.5 | -5.63 | -2.95 | |
Cash per share | 5.84 | 21.94 | 12.39 | 3.84 | 0.35 | |
Book value per share | 3.25 | 22.54 | 13.88 | 7.28 | 1.26 | |
Tangible book value per share | 1.43 | 22.08 | 13.75 | 6.72 | 0.82 | |
Share holders equity per share | 3.25 | 22.54 | 13.88 | 7.28 | 1.26 | |
Interest debt per share | 35.38 | 14.08 | 4.5 | 3.35 | 1.39 | |
Market cap | 264.96M | 2.79B | 5.91B | 1.13B | 149.39M | |
Enterprise value | 285.43M | 2.77B | 5.86B | 1.14B | 162.16M | |
P/E ratio | -15.06 | -147.4 | -254 | -22.23 | -5.1 | |
Price to sales ratio | 131.3 | 1.7K | 2.49K | 475.76 | 0 | |
POCF ratio | -18.96 | -208.92 | -196.51 | -30.25 | -4.91 | |
PFCF ratio | -17.71 | -192.3 | -167.71 | -23.09 | -4.13 | |
P/B Ratio | 107.58 | 49.24 | 54.41 | 17.86 | 9.71 | |
PTB ratio | 107.58 | 49.24 | 54.41 | 17.86 | 9.71 | |
EV to sales | 141.44 | 1.69K | 2.47K | 477.9 | 0 | |
Enterprise value over EBITDA | -20.46 | -235.66 | -189.39 | -24.92 | -5.53 | |
EV to operating cash flow | -20.42 | -207.26 | -195.02 | -30.39 | -5.33 | |
EV to free cash flow | -19.07 | -190.76 | -166.45 | -23.19 | -4.48 | |
Earnings yield | -0.07 | -0.01 | 0 | -0.04 | -0.2 | |
Free cash flow yield | -0.06 | -0.01 | -0.01 | -0.04 | -0.24 | |
Debt to equity | 10.1 | 0.58 | 0.3 | 0.44 | 1.11 | |
Debt to assets | 0.81 | 0.35 | 0.22 | 0.28 | 0.41 | |
Net debt to EBITDA | -1.47 | 1.89 | 1.44 | -0.11 | -0.44 | |
Current ratio | 1.39 | 11.79 | 15.74 | 1.48 | 1.22 | |
Interest coverage | -8.31 | -5.68 | -12.68 | -35.19 | 353.14 | |
Income quality | 0.79 | 0.81 | 1.3 | 0.75 | 0.47 | |
Dividend Yield | 0 | 0.01 | 0 | 0 | 0 | |
Payout ratio | 0 | -1.14 | 0 | 0 | -0.02 | |
Sales general and administrative to revenue | 6.11 | 7.59 | 9.29 | 14.32 | 0 | |
Research and developement to revenue | 2.71 | 1.96 | 4.21 | 7.44 | 0 | |
Intangibles to total assets | 0.04 | 0.01 | 0.01 | 0.05 | 0.13 | |
Capex to operating cash flow | 0.07 | 0.09 | 0.17 | 0.31 | 0.19 | |
Capex to revenue | -0.49 | -0.7 | -2.18 | -4.88 | 0 | |
Capex to depreciation | -0.57 | -0.51 | -2.14 | -3.07 | -4.16 | |
Stock based compensation to revenue | 0.12 | 0.24 | 0.67 | 1.84 | 0 | |
Graham number | 41.25 | 61.8 | 30.46 | 30.95 | 8.23 | |
ROIC | -0.3 | -0.13 | -0.18 | -0.52 | -0.76 | |
Return on tangible assets | -0.6 | -0.2 | -0.16 | -0.54 | -0.82 | |
Graham Net | -31.22 | 8.82 | 8.02 | 0.47 | -0.88 | |
Working capital | 1.35M | 56.51M | 97.95M | 14.63M | 4.68M | |
Tangible asset value | 1.08M | 55.46M | 107.62M | 58.63M | 9.99M | |
Net current asset value | -23.32M | 24.17M | 66.2M | 9.15M | 433K | |
Invested capital | 10.1 | 0.58 | 0.3 | 0.44 | 1.11 | |
Average receivables | 86K | 2.86M | 5.58M | 5.81M | 3.15M | |
Average payables | 895.5K | 1.38M | 2.01M | 3.26M | 3.06M | |
Average inventory | 0.5 | 399K | 412.5K | 1.96M | 12.5M | |
Days sales outstanding | 17.54 | 1.25K | 850.69 | 934.33 | 0 | |
Days payables outstanding | 0 | 913.28 | 562.73 | 7.21K | 610.2 | |
Days of inventory on hand | 0 | 414.32 | 6.74 | 6.59K | 6.96K | |
Receivables turnover | 20.8 | 0.29 | 0.43 | 0.39 | 0 | |
Payables turnover | 0 | 0.4 | 0.65 | 0.05 | 0.6 | |
Inventory turnover | 0 | 0.88 | 54.15 | 0.06 | 0.05 | |
ROE | -7.14 | -0.33 | -0.21 | -0.8 | -1.91 | |
Capex per share | -1.31 | -0.46 | -0.66 | -1.33 | -0.47 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -3.43 | -0.48 | -0.35 | -0.24 | -4.42 | |
Operating cash flow per share | -0.78 | -0.29 | -0.29 | -0.22 | -2.54 | |
Free cash flow per share | -1.08 | -0.28 | -0.32 | -0.22 | -2.54 | |
Cash per share | 0.98 | 0.5 | 0.25 | 0.06 | 1.5 | |
Book value per share | 1.92 | 1.32 | 0.89 | 0.55 | 4.96 | |
Tangible book value per share | 1.37 | 0.91 | 0.58 | 0.33 | 2.06 | |
Share holders equity per share | 1.92 | 1.32 | 0.89 | 0.55 | 4.96 | |
Interest debt per share | 2.09 | 1.37 | 0.99 | 0.69 | 8.89 | |
Market cap | 86.07M | 548.45M | 209.89M | 143.81M | 2.54M | |
Enterprise value | 102.77M | 559.88M | 222.66M | 158.96M | 16.22M | |
P/E ratio | -0.64 | -21.72 | -8.7 | -6.26 | -0.08 | |
Price to sales ratio | 0 | 0 | 0 | 2.88K | 0 | |
POCF ratio | -11.27 | -141.65 | -42.23 | -26.93 | -0.54 | |
PFCF ratio | -8.13 | -149.4 | -38.33 | -26.93 | -0.54 | |
P/B Ratio | 4.57 | 31.54 | 13.65 | 10.89 | 0.28 | |
PTB ratio | 4.57 | 31.54 | 13.65 | 10.89 | 0.28 | |
EV to sales | 0 | 0 | 0 | 3.18K | 0 | |
Enterprise value over EBITDA | -10.04 | -93.91 | -48.3 | -33.61 | -3.92 | |
EV to operating cash flow | -13.46 | -144.6 | -44.8 | -29.77 | -3.45 | |
EV to free cash flow | -9.71 | -152.51 | -40.66 | -29.77 | -3.45 | |
Earnings yield | -0.39 | -0.01 | -0.03 | -0.04 | -3.23 | |
Free cash flow yield | -0.12 | -0.01 | -0.03 | -0.04 | -1.85 | |
Debt to equity | 1.08 | 1.03 | 1.11 | 1.26 | 1.79 | |
Debt to assets | 0.39 | 0.41 | 0.41 | 0.44 | 0.48 | |
Net debt to EBITDA | -1.63 | -1.92 | -2.77 | -3.2 | -3.31 | |
Current ratio | 1.38 | 1.22 | 1.22 | 1.11 | 0.91 | |
Interest coverage | -341.06 | -176.26 | -292.06 | -196.27 | -132.24 | |
Income quality | 0.23 | 0.53 | 0.82 | 0.93 | 0.57 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 70.94 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 32.12 | 0 | |
Intangibles to total assets | 0.1 | 0.12 | 0.13 | 0.14 | 0.16 | |
Capex to operating cash flow | 0.39 | -0.05 | 0.1 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -9.88 | 0.71 | -1.66 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 15.3 | 0 | |
Graham number | 12.19 | 3.77 | 2.66 | 1.72 | 22.21 | |
ROIC | -0.77 | -0.16 | -0.17 | -0.17 | -0.15 | |
Return on tangible assets | -0.72 | -0.16 | -0.17 | -0.18 | -0.29 | |
Graham Net | -0.75 | -0.78 | -0.63 | -0.96 | -7.32 | |
Working capital | 10.46M | 4.82M | 4.68M | 2.31M | -1.85M | |
Tangible asset value | 13.43M | 12M | 9.99M | 7.83M | 3.82M | |
Net current asset value | 5.26M | 96K | 433K | -1.45M | -5.13M | |
Invested capital | 1.08 | 1.03 | 1.11 | 1.26 | 1.79 | |
Average receivables | 6.95M | 4.49M | 723K | 102K | 875K | |
Average payables | 4.4M | 3.01M | 1.93M | 1.88M | 1.89M | |
Average inventory | 10.7M | 19.41M | 19.73M | 10.55M | 7.13M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 1.2K | 642.45 | 5.37K | 687.96 | 432.33 | |
Days of inventory on hand | 6.16K | 5.86K | 61.23K | 0 | 3.32K | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.07 | 0.14 | 0.02 | 0.13 | 0.21 | |
Inventory turnover | 0.01 | 0.02 | 0 | 0 | 0.03 | |
ROE | -1.78 | -0.36 | -0.39 | -0.44 | -0.89 | |
Capex per share | -0.3 | 0.02 | -0.03 | 0 | 0 |
IBIO Frequently Asked Questions
What is iBio, Inc. stock symbol ?
iBio, Inc. is a US stock , located in Bryan of Tx and trading under the symbol IBIO
What is iBio, Inc. stock quote today ?
iBio, Inc. stock price is $4.06 today.
Is iBio, Inc. stock public?
Yes, iBio, Inc. is a publicly traded company.